At the news
? BULLISHIMPACT 8/10 6-K filed Apr 8, 2026 at 16:01 ET
Ascendis Pharma released new Week 52 data from its Phase 2 COACH trial showing that TransCon CNP and TransCon hGH combination therapy delivered clinically meaningful improvements in arm span, spinal canal dimensions, and leg alignment in children with achondroplasia. These results extend beyond prior growth velocity data and demonstrate multi-system benefits.
- New data from Week 52 of the Phase 2 COACH trial show combination therapy with TransCon CNP and TransCon hGH significantly improved arm span, spinal canal dimensions (IPD), and lower limb alignment (TFA) in children with achondroplasia.
- TransCon CNP treatment-naïve cohort gained +9.4 cm in arm span, exceeding typical gains from limb-lengthening surgery (~8 cm) and without surgical risks.
- Mean change in L1-L5 interpedicular distance (IPD) was +1.7 mm in treatment-naïve children, a key improvement over monotherapy (+0.6 mm) that may reduce nerve compression risk.
- Tibial femoral angle (TFA) improved by -3.0 degrees, indicating enhanced leg straightening, compared to -1.3 degrees with monotherapy.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access